Treubstraat 1 Rijswijk, EG , 2288 NetherlandsGenScript is a leading global biotechnology corporation providing gene, peptide, protein, CRISPR, and antibody services to biotech, pharma, and academic partners worldwide. Based on its independent and superior gene synthesis technology, GenScript has become the largest gene synthesis provider worldwide. Building upon the strengths of next-generation semiconductor-based DNA synthesis, GenScript provides precise mutant library services supporting antibody and protein optimization. Additional specialized services for monoclonal antibody development expedite the discovery of high-quality antibodies with broad epitope specificities in a cost-effective manner. GenScript offers a broad range of catalog products, therapeutic and diagnostic supporting materials, and research instruments to provide scientists worldwide with simple, fast, and effective research solutions. Continued innovation and development of capabilities and resources have enabled GenScript’s impressive business expansion. In addition to its original CRO platform, GenScript has established a contract development and manufacturing organization (CDMO), a global cell therapy group, and an industrial synthetic products platform. These collective platforms enable GenScript to provide comprehensive solutions for biologics’ discovery and development, CAR-T cell therapy strategies, and the development of industrial enzymes. By 2020, GenScript’s workforce of over 3,000 employees, with ~30% holding Master’s and/or Ph.D. degrees, were located in subsidiaries, R&D, and manufacturing facilities across the US, Europe, and Asia. Over the past 18 years, GenScript has grown exponentially through partnerships with scientists conducting basic life science research, translational biomedical research, and early-stage pharmaceutical development.
175 Briar Ridge Road Ridgefield, Connecticut, 06877 United StatesGenScript is a leading global biotechnology corporation providing gene, peptide, protein, CRISPR, and antibody services to biotech, pharma, and academic partners worldwide. Based on its independent and superior gene synthesis technology, GenScript has become the largest gene synthesis provider worldwide. Building upon the strengths of next-generation semiconductor-based DNA synthesis, GenScript provides precise mutant library services supporting antibody and protein optimization. Additional specialized services for monoclonal antibody development expedite the discovery of high-quality antibodies with broad epitope specificities in a cost-effective manner. GenScript offers a broad range of catalog products, therapeutic and diagnostic supporting materials, and research instruments to provide scientists worldwide with simple, fast, and effective research solutions. Continued innovation and development of capabilities and resources have enabled GenScript’s impressive business expansion. In addition to its original CRO platform, GenScript has established a contract development and manufacturing organization (CDMO), a global cell therapy group, and an industrial synthetic products platform. These collective platforms enable GenScript to provide comprehensive solutions for biologics’ discovery and development, CAR-T cell therapy strategies, and the development of industrial enzymes. By 2020, GenScript’s workforce of over 3,000 employees, with ~30% holding Master’s and/or Ph.D. degrees, were located in subsidiaries, R&D, and manufacturing facilities across the US, Europe, and Asia. Over the past 18 years, GenScript has grown exponentially through partnerships with scientists conducting basic life science research, translational biomedical research, and early-stage pharmaceutical development.
164 Kallang Way #06-12 Solaris @Kallang 164 Singapore, 349248 SingaporeGenScript is a leading global biotechnology corporation providing gene, peptide, protein, CRISPR, and antibody services to biotech, pharma, and academic partners worldwide. Based on its independent and superior gene synthesis technology, GenScript has become the largest gene synthesis provider worldwide. Building upon the strengths of next-generation semiconductor-based DNA synthesis, GenScript provides precise mutant library services supporting antibody and protein optimization. Additional specialized services for monoclonal antibody development expedite the discovery of high-quality antibodies with broad epitope specificities in a cost-effective manner. GenScript offers a broad range of catalog products, therapeutic and diagnostic supporting materials, and research instruments to provide scientists worldwide with simple, fast, and effective research solutions. Continued innovation and development of capabilities and resources have enabled GenScript’s impressive business expansion. In addition to its original CRO platform, GenScript has established a contract development and manufacturing organization (CDMO), a global cell therapy group, and an industrial synthetic products platform. These collective platforms enable GenScript to provide comprehensive solutions for biologics’ discovery and development, CAR-T cell therapy strategies, and the development of industrial enzymes. By 2020, GenScript’s workforce of over 3,000 employees, with ~30% holding Master’s and/or Ph.D. degrees, were located in subsidiaries, R&D, and manufacturing facilities across the US, Europe, and Asia. Over the past 18 years, GenScript has grown exponentially through partnerships with scientists conducting basic life science research, translational biomedical research, and early-stage pharmaceutical development.
Unit 9 Kings Meadow Ferry Hinksey Road Oxford, Oxfordshire, OX2 0DP United KingdomGenScript is a leading global biotechnology corporation providing gene, peptide, protein, CRISPR, and antibody services to biotech, pharma, and academic partners worldwide. Based on its independent and superior gene synthesis technology, GenScript has become the largest gene synthesis provider worldwide. Building upon the strengths of next-generation semiconductor-based DNA synthesis, GenScript provides precise mutant library services supporting antibody and protein optimization. Additional specialized services for monoclonal antibody development expedite the discovery of high-quality antibodies with broad epitope specificities in a cost-effective manner. GenScript offers a broad range of catalog products, therapeutic and diagnostic supporting materials, and research instruments to provide scientists worldwide with simple, fast, and effective research solutions. Continued innovation and development of capabilities and resources have enabled GenScript’s impressive business expansion. In addition to its original CRO platform, GenScript has established a contract development and manufacturing organization (CDMO), a global cell therapy group, and an industrial synthetic products platform. These collective platforms enable GenScript to provide comprehensive solutions for biologics’ discovery and development, CAR-T cell therapy strategies, and the development of industrial enzymes. By 2020, GenScript’s workforce of over 3,000 employees, with ~30% holding Master’s and/or Ph.D. degrees, were located in subsidiaries, R&D, and manufacturing facilities across the US, Europe, and Asia. Over the past 18 years, GenScript has grown exponentially through partnerships with scientists conducting basic life science research, translational biomedical research, and early-stage pharmaceutical development.
No.28 Yongxi Road Jiangning District Nanjing, Jiangsu, 江宁科学园雍熙路28号 ChinaGenScript is a leading global biotechnology corporation providing gene, peptide, protein, CRISPR, and antibody services to biotech, pharma, and academic partners worldwide. Based on its independent and superior gene synthesis technology, GenScript has become the largest gene synthesis provider worldwide. Building upon the strengths of next-generation semiconductor-based DNA synthesis, GenScript provides precise mutant library services supporting antibody and protein optimization. Additional specialized services for monoclonal antibody development expedite the discovery of high-quality antibodies with broad epitope specificities in a cost-effective manner. GenScript offers a broad range of catalog products, therapeutic and diagnostic supporting materials, and research instruments to provide scientists worldwide with simple, fast, and effective research solutions. Continued innovation and development of capabilities and resources have enabled GenScript’s impressive business expansion. In addition to its original CRO platform, GenScript has established a contract development and manufacturing organization (CDMO), a global cell therapy group, and an industrial synthetic products platform. These collective platforms enable GenScript to provide comprehensive solutions for biologics’ discovery and development, CAR-T cell therapy strategies, and the development of industrial enzymes. By 2020, GenScript’s workforce of over 3,000 employees, with ~30% holding Master’s and/or Ph.D. degrees, were located in subsidiaries, R&D, and manufacturing facilities across the US, Europe, and Asia. Over the past 18 years, GenScript has grown exponentially through partnerships with scientists conducting basic life science research, translational biomedical research, and early-stage pharmaceutical development.
Treubstraat 1 2288 EG , Rijswijk NetherlandsGenScript is a leading global biotechnology corporation providing gene, peptide, protein, CRISPR, and antibody services to biotech, pharma, and academic partners worldwide. Based on its independent and superior gene synthesis technology, GenScript has become the largest gene synthesis provider worldwide. Building upon the strengths of next-generation semiconductor-based DNA synthesis, GenScript provides precise mutant library services supporting antibody and protein optimization. Additional specialized services for monoclonal antibody development expedite the discovery of high-quality antibodies with broad epitope specificities in a cost-effective manner. GenScript offers a broad range of catalog products, therapeutic and diagnostic supporting materials, and research instruments to provide scientists worldwide with simple, fast, and effective research solutions. Continued innovation and development of capabilities and resources have enabled GenScript’s impressive business expansion. In addition to its original CRO platform, GenScript has established a contract development and manufacturing organization (CDMO), a global cell therapy group, and an industrial synthetic products platform. These collective platforms enable GenScript to provide comprehensive solutions for biologics’ discovery and development, CAR-T cell therapy strategies, and the development of industrial enzymes. By 2020, GenScript’s workforce of over 3,000 employees, with ~30% holding Master’s and/or Ph.D. degrees, were located in subsidiaries, R&D, and manufacturing facilities across the US, Europe, and Asia. Over the past 18 years, GenScript has grown exponentially through partnerships with scientists conducting basic life science research, translational biomedical research, and early-stage pharmaceutical development.
Treubstraat 1 Rijswijk, EG, 2288 NetherlandsGenScript is a leading global biotechnology corporation providing gene, peptide, protein, CRISPR, and antibody services to biotech, pharma, and academic partners worldwide. Based on its independent and superior gene synthesis technology, GenScript has become the largest gene synthesis provider worldwide. Building upon the strengths of next-generation semiconductor-based DNA synthesis, GenScript provides precise mutant library services supporting antibody and protein optimization. Additional specialized services for monoclonal antibody development expedite the discovery of high-quality antibodies with broad epitope specificities in a cost-effective manner. GenScript offers a broad range of catalog products, therapeutic and diagnostic supporting materials, and research instruments to provide scientists worldwide with simple, fast, and effective research solutions. Continued innovation and development of capabilities and resources have enabled GenScript’s impressive business expansion. In addition to its original CRO platform, GenScript has established a contract development and manufacturing organization (CDMO), a global cell therapy group, and an industrial synthetic products platform. These collective platforms enable GenScript to provide comprehensive solutions for biologics’ discovery and development, CAR-T cell therapy strategies, and the development of industrial enzymes. By 2020, GenScript’s workforce of over 3,000 employees, with ~30% holding Master’s and/or Ph.D. degrees, were located in subsidiaries, R&D, and manufacturing facilities across the US, Europe, and Asia. Over the past 18 years, GenScript has grown exponentially through partnerships with scientists conducting basic life science research, translational biomedical research, and early-stage pharmaceutical development.
Robert Boyleweg 4, Leiden, 2333 CG NetherlandsGenScript is a leading global biotechnology corporation providing gene, peptide, protein, CRISPR, and antibody services to biotech, pharma, and academic partners worldwide. Based on its independent and superior gene synthesis technology, GenScript has become the largest gene synthesis provider worldwide. Building upon the strengths of next-generation semiconductor-based DNA synthesis, GenScript provides precise mutant library services supporting antibody and protein optimization. Additional specialized services for monoclonal antibody development expedite the discovery of high-quality antibodies with broad epitope specificities in a cost-effective manner. GenScript offers a broad range of catalog products, therapeutic and diagnostic supporting materials, and research instruments to provide scientists worldwide with simple, fast, and effective research solutions. Continued innovation and development of capabilities and resources have enabled GenScript’s impressive business expansion. In addition to its original CRO platform, GenScript has established a contract development and manufacturing organization (CDMO), a global cell therapy group, and an industrial synthetic products platform. These collective platforms enable GenScript to provide comprehensive solutions for biologics’ discovery and development, CAR-T cell therapy strategies, and the development of industrial enzymes. By 2020, GenScript’s workforce of over 3,000 employees, with ~30% holding Master’s and/or Ph.D. degrees, were located in subsidiaries, R&D, and manufacturing facilities across the US, Europe, and Asia. Over the past 18 years, GenScript has grown exponentially through partnerships with scientists conducting basic life science research, translational biomedical research, and early-stage pharmaceutical development.
20 Kingsbridge Road Piscataway, NJ, 08854 United StatesGenScript is a leading global biotechnology corporation providing gene, peptide, protein, CRISPR, and antibody services to biotech, pharma, and academic partners worldwide. Based on its independent and superior gene synthesis technology, GenScript has become the largest gene synthesis provider worldwide. Building upon the strengths of next-generation semiconductor-based DNA synthesis, GenScript provides precise mutant library services supporting antibody and protein optimization. Additional specialized services for monoclonal antibody development expedite the discovery of high-quality antibodies with broad epitope specificities in a cost-effective manner. GenScript offers a broad range of catalog products, therapeutic and diagnostic supporting materials, and research instruments to provide scientists worldwide with simple, fast, and effective research solutions. Continued innovation and development of capabilities and resources have enabled GenScript’s impressive business expansion. In addition to its original CRO platform, GenScript has established a contract development and manufacturing organization (CDMO), a global cell therapy group, and an industrial synthetic products platform. These collective platforms enable GenScript to provide comprehensive solutions for biologics’ discovery and development, CAR-T cell therapy strategies, and the development of industrial enzymes. By 2020, GenScript’s workforce of over 3,000 employees, with ~30% holding Master’s and/or Ph.D. degrees, were located in subsidiaries, R&D, and manufacturing facilities across the US, Europe, and Asia. Over the past 18 years, GenScript has grown exponentially through partnerships with scientists conducting basic life science research, translational biomedical research, and early-stage pharmaceutical development.
860 Centennial Ave Piscataway, NJ, 08854 United StatesGenScript is a leading global biotechnology corporation providing gene, peptide, protein, CRISPR, and antibody services to biotech, pharma, and academic partners worldwide. Based on its independent and superior gene synthesis technology, GenScript has become the largest gene synthesis provider worldwide. Building upon the strengths of next-generation semiconductor-based DNA synthesis, GenScript provides precise mutant library services supporting antibody and protein optimization. Additional specialized services for monoclonal antibody development expedite the discovery of high-quality antibodies with broad epitope specificities in a cost-effective manner. GenScript offers a broad range of catalog products, therapeutic and diagnostic supporting materials, and research instruments to provide scientists worldwide with simple, fast, and effective research solutions. Continued innovation and development of capabilities and resources have enabled GenScript’s impressive business expansion. In addition to its original CRO platform, GenScript has established a contract development and manufacturing organization (CDMO), a global cell therapy group, and an industrial synthetic products platform. These collective platforms enable GenScript to provide comprehensive solutions for biologics’ discovery and development, CAR-T cell therapy strategies, and the development of industrial enzymes. By 2020, GenScript’s workforce of over 3,000 employees, with ~30% holding Master’s and/or Ph.D. degrees, were located in subsidiaries, R&D, and manufacturing facilities across the US, Europe, and Asia. Over the past 18 years, GenScript has grown exponentially through partnerships with scientists conducting basic life science research, translational biomedical research, and early-stage pharmaceutical development.
GenScript 860 Centennial Ave. Piscataway, NJ, 08854 United StatesGenScript is a leading global biotechnology corporation providing gene, peptide, protein, CRISPR, and antibody services to biotech, pharma, and academic partners worldwide. Based on its independent and superior gene synthesis technology, GenScript has become the largest gene synthesis provider worldwide. Building upon the strengths of next-generation semiconductor-based DNA synthesis, GenScript provides precise mutant library services supporting antibody and protein optimization. Additional specialized services for monoclonal antibody development expedite the discovery of high-quality antibodies with broad epitope specificities in a cost-effective manner. GenScript offers a broad range of catalog products, therapeutic and diagnostic supporting materials, and research instruments to provide scientists worldwide with simple, fast, and effective research solutions. Continued innovation and development of capabilities and resources have enabled GenScript’s impressive business expansion. In addition to its original CRO platform, GenScript has established a contract development and manufacturing organization (CDMO), a global cell therapy group, and an industrial synthetic products platform. These collective platforms enable GenScript to provide comprehensive solutions for biologics’ discovery and development, CAR-T cell therapy strategies, and the development of industrial enzymes. By 2020, GenScript’s workforce of over 3,000 employees, with ~30% holding Master’s and/or Ph.D. degrees, were located in subsidiaries, R&D, and manufacturing facilities across the US, Europe, and Asia. Over the past 18 years, GenScript has grown exponentially through partnerships with scientists conducting basic life science research, translational biomedical research, and early-stage pharmaceutical development.
175 Briar Ridge Road Ridgefield, CT, 06877 United StatesGenScript is a leading global biotechnology corporation providing gene, peptide, protein, CRISPR, and antibody services to biotech, pharma, and academic partners worldwide. Based on its independent and superior gene synthesis technology, GenScript has become the largest gene synthesis provider worldwide. Building upon the strengths of next-generation semiconductor-based DNA synthesis, GenScript provides precise mutant library services supporting antibody and protein optimization. Additional specialized services for monoclonal antibody development expedite the discovery of high-quality antibodies with broad epitope specificities in a cost-effective manner. GenScript offers a broad range of catalog products, therapeutic and diagnostic supporting materials, and research instruments to provide scientists worldwide with simple, fast, and effective research solutions. Continued innovation and development of capabilities and resources have enabled GenScript’s impressive business expansion. In addition to its original CRO platform, GenScript has established a contract development and manufacturing organization (CDMO), a global cell therapy group, and an industrial synthetic products platform. These collective platforms enable GenScript to provide comprehensive solutions for biologics’ discovery and development, CAR-T cell therapy strategies, and the development of industrial enzymes. By 2020, GenScript’s workforce of over 3,000 employees, with ~30% holding Master’s and/or Ph.D. degrees, were located in subsidiaries, R&D, and manufacturing facilities across the US, Europe, and Asia. Over the past 18 years, GenScript has grown exponentially through partnerships with scientists conducting basic life science research, translational biomedical research, and early-stage pharmaceutical development.
311 Pennington Rocky Hill Rd Pennington, NJ, 08534 United StatesGenScript is a leading global biotechnology corporation providing gene, peptide, protein, CRISPR, and antibody services to biotech, pharma, and academic partners worldwide. Based on its independent and superior gene synthesis technology, GenScript has become the largest gene synthesis provider worldwide. Building upon the strengths of next-generation semiconductor-based DNA synthesis, GenScript provides precise mutant library services supporting antibody and protein optimization. Additional specialized services for monoclonal antibody development expedite the discovery of high-quality antibodies with broad epitope specificities in a cost-effective manner. GenScript offers a broad range of catalog products, therapeutic and diagnostic supporting materials, and research instruments to provide scientists worldwide with simple, fast, and effective research solutions. Continued innovation and development of capabilities and resources have enabled GenScript’s impressive business expansion. In addition to its original CRO platform, GenScript has established a contract development and manufacturing organization (CDMO), a global cell therapy group, and an industrial synthetic products platform. These collective platforms enable GenScript to provide comprehensive solutions for biologics’ discovery and development, CAR-T cell therapy strategies, and the development of industrial enzymes. By 2020, GenScript’s workforce of over 3,000 employees, with ~30% holding Master’s and/or Ph.D. degrees, were located in subsidiaries, R&D, and manufacturing facilities across the US, Europe, and Asia. Over the past 18 years, GenScript has grown exponentially through partnerships with scientists conducting basic life science research, translational biomedical research, and early-stage pharmaceutical development.
The Contract Research Map is owned and maintained by Scientist.com. It was created to help researchers in the life sciences identify and connect with contract research organizations (CROs) based on geography. Updated nightly, this map features all of the available CROs within our network, so you can order services with a few clicks. Click on a specific country, scroll on the map itself or type into the search bar at the top—there are many ways to find the location and suppliers that you’re looking for. From Argentina to New Zealand, use this map to connect with a CRO near you.
We believe that every researcher across the world should be able to connect with the thousands of global CROs that exist and have the opportunity to work together. Like many industries,the life science supply chain has been disrupted over the last year. But there are many other circumstances such as international customs regulations or sensitive shipping times that create limitations around which countries are feasible to partner with. Sometimes, finding a CRO based in a country that best suits your research needs is imperative. We hope this contract research map allows you to find the right partner in the right place at the right time.
Have questions or feedback? We’d love to help. You can find our FAQs and contact information on the Learn more page.
Interested in connecting with one or more of the contract research organizations listed on this map? By clicking on the company’s name, you will be directed to their supplier profile on the Scientist.com marketplace. Once you set up a marketplace account you can start the ordering process immediately.
Scientist.com is the world's largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies.
Scientist.com has built private, enterprise marketplaces from 24 of the 30 largest pharmaceutical companies, 80+ biotech companies, the US National Institutes of Health (NIH) and numerous other pharma and biotech companies. If you are employed by one of these organizations, you can log in to get started today. If you are unsure about how to get started, you can email our team at support@scientist.com or go to our website www.scientist.comto speak to someone via our live chat.
Scientist.com is a highly efficient enterprise-wide outsourcing marketplace that makes it possible for research organizations to save time and money, access innovation and ensure compliance. It utilizes a universal legal agreement and AI technologies to enable research like never before. See how comparing proposals and getting 1-on-1 support from our Research Concierge® team will enable you to place more research today.
If your CRO isn’t showing up on the map, then please be sure your company profile is up to date in Scientist.com’s Backoffice. After logging in, click the Your Company button in the navigation at the top, and then select the Locations tab.
Head over to backoffice.scientist.com to update your supplier profile and information. It may take up to two business days for the updates to be reflected on the map.